

Cipla launches pneumotach-based portable, wireless spirometer, Spirofy

17 November 2021 | News

Spirofy is India's first pneumotach based portable wireless Spirometer for diagnosis of COPD and asthma



Cipla has announced the launch of Spirofy, India's first pneumotach-based portable, wireless spirometer, on World Chronic obstructive pulmonary disease (COPD) Day. With the launch, the company intends to revolutionise Obstructive Airway Disease (OAD) diagnosis, in line with its ambition to strengthen its position as the lung leader in India. This a part of the company's #LungAttack campaign that endeavors to drive awareness about COPD and encourage early diagnosis.

Cipla's Spirofy is a result of five years of in-house research by the Integrated Product Development (IPD) team, and it aims to transform Obstructive Airway Disease (OAD) diagnosis in India. This advanced device ensures high result accuracy and individual patient safety using Bacterial Viral Filters. Spirofy is entirely wireless with good battery backup, making it suitable for use in outdoor camps, remote areas with power shortages, or simply providing physicians' flexibility and ease of use.

The device generates reports in real-time, which can be printed using a portable wireless thermal printer instantly, or a pdf version can be shared on the phone. Cipla will undertake the training of physicians in the interpretation of spirometry results.

Spirometry is the gold standard for COPD diagnosis, however owing to the bulky size, complex functionality, need for regular maintenance are some reasons that impacted the widespread acceptance of conventional spirometers by medical practitioners. This resulted in underdiagnosis or misdiagnosis of COPD cases in India. Currently, COPD remains the second most common cause of death in India after heart diseases, where India alone bears 32 per cent of the global COPD burden.